Repare Therapeutics (RPTX) Competitors

Repare Therapeutics (NASDAQ:RPTX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Is RPTX or LRMR more profitable?

Larimar Therapeutics has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. Larimar Therapeutics' return on equity of -35.87% beat Repare Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repare Therapeutics	-99.76%	-40.87%	-35.07%
Larimar Therapeutics	N/A	-35.87%	-32.37%

Does the media prefer RPTX or LRMR?

In the previous week, Repare Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 1 mentions for Repare Therapeutics and 0 mentions for Larimar Therapeutics. Repare Therapeutics' average media sentiment score of 0.32 beat Larimar Therapeutics' score of 0.00 indicating that Repare Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Repare Therapeutics	Neutral
Larimar Therapeutics	Neutral

Do analysts recommend RPTX or LRMR?

Repare Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 446.88%. Larimar Therapeutics has a consensus target price of $20.43, suggesting a potential upside of 511.63%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Repare Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repare Therapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Larimar Therapeutics	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09

Which has more risk and volatility, RPTX or LRMR?

Repare Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Does the MarketBeat Community prefer RPTX or LRMR?

Repare Therapeutics received 2 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 68.97% of users gave Larimar Therapeutics an outperform vote while only 63.64% of users gave Repare Therapeutics an outperform vote.

Company	Underperform	Outperform
Repare Therapeutics	Outperform Votes 42 63.64%	Underperform Votes 24 36.36%
Larimar Therapeutics	Outperform Votes 40 68.97%	Underperform Votes 18 31.03%

Which has higher valuation and earnings, RPTX or LRMR?

Larimar Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repare Therapeutics	$51.13M	1.06	-$93.80M	-$2.00	-0.64
Larimar Therapeutics	N/A	N/A	-$36.95M	-$1.15	-2.90

Do insiders & institutionals believe in RPTX or LRMR?

85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 21.6% of Repare Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Larimar Therapeutics beats Repare Therapeutics on 12 of the 17 factors compared between the two stocks.